Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.

Autor: Ruperto N; Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, PRINTO, Genoa, Italy. nicolaruperto@gaslini.org., Brunner HI; Cincinnati Children's Hospital Medical Center, PRCSG, Cincinnati, OH, USA., Zuber Z; St Louis Children's Hospital ODS Rheumatology and Neurology, Krakow, Poland., Tzaribachev N; Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany., Kingsbury DJ; Randall Children's Hospital, Portland, OR, USA., Foeldvari I; Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany., Horneff G; Centre of General Pediatrics and Neonatology, Asklepios Klinik, Sankt Augustin, Germany., Smolewska E; Department of Pediatric Rheumatology, Medical University of Lodz, Lodz, Poland., Vehe RK; University of Minnesota Masonic Children's Hospital, Minneapolis, MN, USA., Hazra A; Pfizer Inc, Collegeville, PA, USA., Wang R; Pfizer Inc, Groton, CT, USA., Mebus CA; Pfizer Inc, Groton, CT, USA., Alvey C; Pfizer Inc, Groton, CT, USA., Lamba M; Pfizer Inc, Groton, CT, USA., Krishnaswami S; Pfizer Inc, Groton, CT, USA., Stock TC; Pfizer Inc, Collegeville, PA, USA., Wang M; Pfizer Inc, Collegeville, PA, USA., Suehiro R; Pfizer Inc, Collegeville, PA, USA., Martini A; Istituto Giannina Gaslini, Direzione Scientifica, Genoa, Italy., Lovell DJ; Cincinnati Children's Hospital Medical Center, PRCSG, Cincinnati, OH, USA.

Publikováno v: Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2017 Dec 28; Vol. 15 (1), pp. 86. Date of Electronic Publication: 2017 Dec 28.

Model-based drug development: a rational approach to efficiently accelerate drug development.

Autor: Milligan PA; Global Clinical Pharmacology, Pfizer, Sandwich, UK. peter.a.milligan@pfizer.com, Brown MJ, Marchant B, Martin SW, van der Graaf PH, Benson N, Nucci G, Nichols DJ, Boyd RA, Mandema JW, Krishnaswami S, Zwillich S, Gruben D, Anziano RJ, Stock TC, Lalonde RL

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2013 Jun; Vol. 93 (6), pp. 502-14. Date of Electronic Publication: 2013 Mar 14.

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.

Autor: Fleishaker DL; Pfizer Inc, 700 Chesterfield Parkway, St, Louis, MO, 63017, and Eastern Point Road, Groton, CT, 06340 USA. dona.l.fleishaker@pfizer.com, Garcia Meijide JA, Petrov A, Kohen MD, Wang X, Menon S, Stock TC, Mebus CA, Goodrich JM, Mayer HB, Zeiher BG

Publikováno v: Arthritis research & therapy [Arthritis Res Ther] 2012 Jan 17; Vol. 14 (1), pp. R11. Date of Electronic Publication: 2012 Jan 17.